MeSH term
Frequency | Condition_Probility | Adolescent | 6 | 0.0 |
Adult | 29 | 0.0 |
Aged | 22 | 0.0 |
Chronic Disease | 3 | 0.0 |
Female | 44 | 0.0 |
Humans | 111 | 0.0 |
Male | 44 | 0.0 |
Middle Aged | 28 | 0.0 |
Research Support, Non-U.S. Gov't | 64 | 0.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Chimeric Proteins/*immunology | 2 | 25.0 |
Flow Cytometry | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Animals | 35 | 0.0 |
Carbonic Anhydrases/*genetics | 9 | 34.0 |
Chromosome Mapping | 5 | 0.0 |
Mice | 17 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Calcium/metabolism | 5 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Phosphorylation | 3 | 0.0 |
Protein Binding | 3 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Temperature | 2 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Disease Progression | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 23 | 0.0 |
Survival Rate | 2 | 0.0 |
Transfection | 3 | 0.0 |
Xenopus | 2 | 0.0 |
Autoradiography | 7 | 1.0 |
Cell Count | 5 | 0.0 |
In Vitro | 5 | 0.0 |
Antibodies, Monoclonal/immunology/therapeutic use | 2 | 10.0 |
Arthritis, Rheumatoid/immunology/*therapy | 2 | 9.0 |
Crohn Disease/immunology/*therapy | 2 | 40.0 |
English Abstract | 5 | 0.0 |
Treatment Outcome | 7 | 0.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology | 5 | 26.0 |
Age Factors | 2 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Hippocampus/*pathology | 7 | 13.0 |
Neurofibrillary Tangles/*pathology | 4 | 18.0 |
Neurons/pathology | 4 | 3.0 |
Severity of Illness Index | 4 | 0.0 |
Child | 4 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Inflammatory Bowel Diseases/*drug therapy | 3 | 27.0 |
Survival Analysis | 2 | 0.0 |
Time Factors | 6 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Base Sequence | 5 | 0.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Molecular Sequence Data | 8 | 0.0 |
Rats | 8 | 0.0 |
Antibodies, Monoclonal/therapeutic use | 2 | 1.0 |
Comparative Study | 18 | 0.0 |
Infusions, Intravenous | 9 | 1.0 |
Alzheimer Disease/*metabolism/pathology | 2 | 2.0 |
Leukocyte Count | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*immunology/metabolism | 3 | 15.0 |
Antibodies, Monoclonal/*therapeutic use | 11 | 3.0 |
Clinical Trials | 5 | 0.0 |
Alzheimer Disease/*pathology | 3 | 5.0 |
Glial Fibrillary Acidic Protein/analysis | 2 | 1.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Child, Preschool | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
T-Lymphocytes/*drug effects | 2 | 2.0 |
Tumor Necrosis Factor-alpha/*antagonists & inhibitors | 2 | 2.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Ecuador | 2 | 18.0 |
Phenotype | 4 | 0.0 |
Amino Acid Sequence | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*immunology | 13 | 11.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
Brain Ischemia/*pathology | 2 | 28.0 |
Species Specificity | 4 | 0.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Cell Line | 5 | 0.0 |
Double-Blind Method | 7 | 0.0 |
Arthritis, Rheumatoid/*therapy | 4 | 22.0 |
C-Reactive Protein/analysis | 3 | 0.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Safety | 2 | 1.0 |
Remission Induction | 3 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Calcium/*metabolism | 3 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Nerve Tissue Proteins/*analysis | 2 | 2.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Lymphocyte Activation | 4 | 0.0 |
C-Reactive Protein/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Interleukin-6/blood | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Antibodies, Monoclonal/adverse effects/*therapeutic use | 2 | 5.0 |
Brain Mapping | 2 | 1.0 |
Blood Sedimentation | 2 | 1.0 |
Rats, Wistar | 3 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
*Chromosomes, Human, Pair 8 | 5 | 2.0 |
Antibodies, Monoclonal/administration & dosage/*pharmacology | 2 | 25.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Alleles | 3 | 0.0 |
Carbonic Anhydrases/genetics | 2 | 22.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Gene Frequency | 4 | 0.0 |
*Genetics, Population | 3 | 0.0 |
Haplotypes | 3 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Pregnancy | 3 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Recurrence | 2 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Chromosome Banding | 3 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Cricetulus | 2 | 0.0 |
DNA Probes | 4 | 0.0 |
Hamsters | 3 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Karyotyping | 3 | 0.0 |
Sheep/*genetics | 2 | 3.0 |
Neutralization Tests | 2 | 0.0 |
Genetic Markers | 5 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Autopsy | 2 | 1.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
Biological Transport | 3 | 0.0 |
Calcium/physiology | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Isoenzymes/*genetics | 3 | 0.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Histocytochemistry | 2 | 0.0 |
Guinea Pigs | 2 | 0.0 |
Inositol 1,4,5-Trisphosphate | 2 | 11.0 |
Calcium/*blood | 2 | 2.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Egtazic Acid/pharmacology | 2 | 1.0 |
Kinetics | 2 | 0.0 |
*Chromosomes, Human, 6-12 and X | 2 | 1.0 |
